Biofrontera Inc.
BFRI
$0.7874
-$0.0136-1.70%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 37.32M | 35.36M | 35.24M | 33.25M | 34.07M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.32M | 35.36M | 35.24M | 33.25M | 34.07M |
| Cost of Revenue | 18.61M | 18.70M | 18.42M | 16.96M | 17.44M |
| Gross Profit | 18.72M | 16.66M | 16.83M | 16.29M | 16.63M |
| SG&A Expenses | 33.84M | 34.68M | 34.95M | 38.44M | 37.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.53M | 54.72M | 54.07M | 55.50M | 55.42M |
| Operating Income | -17.21M | -19.36M | -18.82M | -22.24M | -21.35M |
| Income Before Tax | -17.74M | -12.82M | -13.49M | -23.08M | -20.12M |
| Income Tax Expenses | 21.00K | 18.00K | 16.00K | 10.00K | 14.00K |
| Earnings from Continuing Operations | -17.76 | -12.84 | -13.51 | -23.09 | -20.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.76M | -12.84M | -13.51M | -23.09M | -20.13M |
| EBIT | -17.21M | -19.36M | -18.82M | -22.24M | -21.35M |
| EBITDA | -16.79M | -18.85M | -18.31M | -21.74M | -20.85M |
| EPS Basic | -4.10 | -2.27 | -5.92 | -13.10 | -15.82 |
| Normalized Basic EPS | -2.63 | -3.32 | -4.51 | -8.22 | -8.16 |
| EPS Diluted | -4.28 | -2.27 | -5.92 | -13.10 | -15.82 |
| Normalized Diluted EPS | -2.63 | -3.32 | -4.51 | -8.22 | -8.16 |
| Average Basic Shares Outstanding | 22.06M | 16.63M | 12.22M | 8.49M | 6.20M |
| Average Diluted Shares Outstanding | 22.06M | 16.63M | 12.22M | 8.49M | 6.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
